Alcon launches Hydrus Microstent in India to transform glaucoma care
The Hydrus Microstent stands out as the first and only MIGS device backed by five-year clinical outcomes
The Hydrus Microstent stands out as the first and only MIGS device backed by five-year clinical outcomes
Germany will be the first launch market
The first of four planned modules at the new plant is expected to come online by summer 2026
The company says those insights can power advanced analytics and real-world evidence (RWE), helping researchers improve trial design, study feasibility, and recruitment strategies
ShunzymeX leverages a proprietary protease to streamline purification
It is also approved for?AIDS-related Kaposi sarcoma?after failure of highly active antiretroviral therapy, as well as for HIV-negative adult patients with Kaposi sarcoma
Built on the Percept Platform and enhanced with BrainSense technology, the system can adjust stimulation levels in real time, responding to brain signals without manual intervention
SYNT-101 is a once-daily oral pill engineered to redirect nutrient absorption beyond the small intestine’s duodenum
The product addresses a market with approximately $66.8 million in annual sales as of December 2025.
Subscribe To Our Newsletter & Stay Updated